IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3021% above fair value
$0.18−0.01 (-7.24%)
Close on Nov 12, 2026Market cap $19.07MP/E –Yield –
IGC Pharma operating margin
Operating margin is operating income as a percentage of revenue.
IGC Pharma's operating margin for the twelve months ending Jun 30, 2026 was -986.8%. For fiscal 2025 it was -585.8%, against -728.5% the year before. The highest annual figure on record is -30.9% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -585.8% | +142.6 |
| FY2024 | Mar 31, 2024 | -728.5% | +541.7 |
| FY2023 | Mar 31, 2023 | -1270.1% | +2616.0 |
| FY2022 | Mar 31, 2022 | -3886.1% | −2914.7 |
| FY2021 | Mar 31, 2021 | -971.5% | −802.9 |
| FY2020 | Mar 31, 2020 | -168.6% | −77.8 |
| FY2019 | Mar 31, 2019 | -90.8% | −9.2 |
| FY2018 | Mar 31, 2018 | -81.6% | +272.4 |
| FY2017 | Mar 31, 2017 | -354.0% | −308.3 |
| FY2016 | Mar 31, 2016 | -45.6% | +10.9 |
| FY2015 | Mar 31, 2015 | -56.5% | +54.7 |
| FY2014 | Mar 31, 2014 | -111.2% | −80.3 |
| FY2013 | Mar 31, 2013 | -30.9% | +147.9 |
| FY2012 | Mar 31, 2012 | -178.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -1050.6% | −469.8 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -775.4% | −347.2 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -840.3% | −109.5 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -1517.8% | −1090.6 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -580.8% | +300.1 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -428.2% | +307.4 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -730.7% | +738.9 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -427.2% | +428.8 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -880.9% | −495.5 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -735.6% | +1697.5 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -1469.6% | −783.5 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -856.0% | +375.7 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -385.4% | +936.3 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -2433.1% | +2895.6 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -686.1% | +993.4 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -1231.7% | +6532.6 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -1321.7% | +1527.7 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -5328.7% | −1883.0 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -1679.6% | +474.1 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -7764.3% | −6423.5 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -2849.4% | −2518.7 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -3445.7% | +4978.5 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -2153.7% | −1860.9 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -1340.8% | −1270.1 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -330.7% | −242.4 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -8424.1% | −8314.0 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -292.8% | −170.0 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -70.7% | +34.7 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -88.2% | −53.7 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -110.1% | −47.6 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -122.8% | −60.7 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -105.4% | +6.5 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -34.6% | +714.1 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -62.5% | +727.8 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -62.1% | +92.5 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -111.9% | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -748.7% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -790.4% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -154.6% | – |
See a number that looks wrong?